Nkarta

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Nkarta and other ETFs, options, and stocks.

About NKTX

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. 

CEO
Paul J. Hastings
CEOPaul J. Hastings
Employees
136
Employees136
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2005
Founded2005
Employees
136
Employees136

NKTX Key Statistics

Market cap
640.32M
Market cap640.32M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
413.20K
Average volume413.20K
High today
$13.66
High today$13.66
Low today
$12.58
Low today$12.58
Open price
$12.59
Open price$12.59
Volume
254.51K
Volume254.51K
52 Week high
$27.82
52 Week high$27.82
52 Week low
$7.55
52 Week low$7.55

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

NKTX Earnings

-$0.90
-$0.60
-$0.30
-$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 9, After Hours
ActualExpected Nov 9, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.